GDF15 dynamics during weight loss—with a non-significant trend to slightly elevated concentrations after 3 months and significant reduction after 12 months—were independent of hypertension and therapeutical strategy (Figure 4C–E). Here, GDF15 is linked to hypertensive disorder.